Ocugen (MEX:OCGN) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ocugen Days Payable?

Ocugen's average Accounts Payable for the three months ended in Dec. 2024 was MXN58.95 Mil. Ocugen's Cost of Goods Sold for the three months ended in Dec. 2024 was MXN0.00 Mil.

The historical rank and industry rank for Ocugen's Days Payable or its related term are showing as below:

MEX:OCGN's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 118.245
* Ranked among companies with meaningful Days Payable only.

Ocugen's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Ocugen Days Payable Historical Data

The historical data trend for Ocugen's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Days Payable Chart

Ocugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Ocugen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ocugen's Days Payable

For the Biotechnology subindustry, Ocugen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Days Payable distribution charts can be found below:

* The bar in red indicates where Ocugen's Days Payable falls into.

Save Embed

;

Save Embed

;

Ocugen Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Ocugen's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (53.842	+	88.491)	/	2 )	/	0	*	365
=	71.1665					/	0	*	365
=	N/A

Ocugen's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (29.417	+	88.491)	/	2 )	/	0	*	365 / 4
=	58.954					/	0	*	365 / 4
=	N/A

Ocugen Days Payable Related Terms

Thank you for viewing the detailed overview of Ocugen's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

OCGN:USA 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").